Claro Scientific announces Notice of Allowance from U.S. Patent and Trademark Office for Blood Culture.
Latest News
Claro Scientific wins first place in the early stage shoot out competition at SEBIO.
Tom McLain, Claro’s CEO will be presenting at Southeast Bio conference on Tuesday November 1 and ibiliti’s medtech 11 conference on Wednesday November 2 in Chapel Hill, North Carolina.
Claro Scientific is testing blood by using beams of light rather than chemicals.
Tom McLain, Claro’s CEO will be presenting at that AvaMed 2011 conference on Tuesday September 27.
Dr. Luis Garcia-Rubio, Claro’s Chief Scientific Officer, presents results from Claro’s Protein Solutions.
Claro is part of the progress in eliminating malaria deaths by advancing a combined malaria and anemia rapid diagnostic test using our SpectraWave system.
Claro Scientific today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for Claro’s claims for the use of real-time monitoring of blood cultures for pathogen detection entitled “Detecting Microorganisms in Blood Utilizing Physical and Chemical Changes in Blood.”
Dr. Jennifer Smith, Claro’s Principal Scientist, will be presenting results from an on-going clinical study for the identification of bacterial pathogens.
Award recognizes cutting edge private companies driving the future of innovation.